[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-331547-105":59,"doc-detail-331547-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","rere-as1-enhances-the-effect-of-cdk46-inhibitor-ribociclib-and-suppresses-malignant-phenotype-in-breast-cancer-via-mekerk-pathway","RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway","","Background: Lack of biomarkers limits identifying breast cancer patients who benefit from CDK4/6 inhibitors. This study integrates machine learning on transcriptomic data with in vivo and in vitro experiments to find biomarkers linked to ribociclib efficacy from the perspective of long non-coding RNA (lncRNA). Methods: The Genomics of Drug Sensitivity in Cancer database and the oncoPredict algorithm estimate ribociclib IC50, then ML selects key lncRNAs. Cellular, correlation, RT-qPCR, and pan-cancer analyses evaluate expression patterns and diagnostic/prognostic value.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/rere-as1-enhances-the-effect-of-cdk46-inhibitor-ribociclib-and-suppresses-malignant-phenotype-in-breast-cancer-via-mekerk-pathway/331547/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/rere-as1-enhances-the-effect-of-cdk46-inhibitor-ribociclib-and-suppresses-malignant-phenotype-in-breast-cancer-via-mekerk-pathway/331547.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address regarding CDK4/6 inhibitors in breast cancer?","Question",{"text":112,"@type":113},"The study addresses the lack of biomarkers that can identify which breast cancer patients will benefit from CDK4/6 inhibitors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were ribociclib efficacy-related biomarkers identified?",{"text":117,"@type":113},"The researchers used transcriptomic data with the Genomics of Drug Sensitivity in Cancer database and the oncoPredict algorithm to estimate IC50 values, then applied machine learning to select key lncRNAs and build a predictive model.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the main finding about RERE-AS1 and ribociclib in breast cancer cells?",{"text":121,"@type":113},"Overexpression of RERE-AS1 promotes ribociclib’s antitumor activity and suppresses malignant traits by reducing MEK and ERK phosphorylation levels.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},331547,1790122221,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Huang et al. Journal of Translational Medicine (2024) 22:1052  \n[https://doi.org/10.1186/s12967-024-05828-x](https://doi.org/10.1186/s12967-024-05828-x)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nRERE-AS1  \nenhances the effect of CDK4/6  \ninhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway  \nZhidong Huang1, Kaixin Lou1, Mengyang Qi1, Jinhui Wang1, Linwei Li1, Bo Sun1, Chen Wang4, Xirui Zhou4, Debo Chen2,3* and Hong Liu 1*  \nAbstract  \nBackground Currently, there is a lack of biomarkers to identify breast cancer (BC) patients who would benefit from CDK4/6 inhibitors. This study combined machine learning (ML) algorithms based on transcriptomic data  \nwith both in vivo and in vitro experiments to identify therapeutic efficacy-related biomarkers of the CDK4/6 inhibitor ribociclib from the perspective of long non-coding RNA (lncRNA) .  \nMethods We used the Genomics of Drug Sensitivity in Cancer database along with the “oncoPredict” algorithm to calculate the half maximal inhibitory concentration (IC50) values for ribociclib based on transcriptome data. ML algorithms were utilized to select key lncRNAs related to ribociclib and to establish a model which could be used for selection of potential beneficiaries of ribociclib. Cellular experiments were conducted to validate the ML analysis and explore the potential biological mechanisms by which RERE-AS1 influences ribociclib efficacy and malignant phenotype of BC cells. Correlation analysis with clinical pathological factors, RT-qPCR experiments on tissue specimens, and pan-cancer analysis were carried out to explore the expression pattern, and the prognostic and diagnostic potential of RERE-AS1 in cancers.  \nResults We have identified 11 key ribociclib-related lncRNAs and constructed an artificial neural network model (ANNM) based on lncRNA. Cellular experiments demonstrated that overexpression of RERE-AS1 promoted the antitumor activity of ribociclib in BC cells. Furthermore, RERE-AS1 is crucial in suppressing the malignant traits of BC cells through the reduction of MEK and ERK phosphorylation levels. Patients with smaller primary tumors and lower pathological stage exhibited higher levels of RERE-AS1 expression. Lastly, a pan-cancer analysis revealed that REREAS1 exhibits distinctly abnormal expression patterns, prognostic significance, and clinical diagnostic value in BC, compared to other cancers.  \nConclusions The ANNM established through ML algorithms can serve as predictive indicators for the efficacy of ribociclib in BC patients. LncRNA RERE-AS1, a newly discovered biomarker, holds significant promise for diagnosis, treatment, and enhancing the therapeutic response to ribociclib in BC.  \n*Correspondence:  \nDebo Chen [debochensr@fjmu.edu.cn](debochensr@fjmu.edu.cn)[ ](debochensr@fjmu.edu.cn)Hong Liu [liuhong_submit@tjmuch.com](liuhong_submit@tjmuch.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creative","cbCaijzpFzWQTrlU","https://ap.wps.com/l/cbCaijzpFzWQTrlU","pdf",6262324,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Graphical Abstract\n## Background","[{\"question\":\"What problem does the study address regarding CDK4/6 inhibitors in breast cancer?\",\"answer\":\"The study addresses the lack of biomarkers that can identify which breast cancer patients will benefit from CDK4/6 inhibitors.\"},{\"question\":\"How were ribociclib efficacy-related biomarkers identified?\",\"answer\":\"The researchers used transcriptomic data with the Genomics of Drug Sensitivity in Cancer database and the oncoPredict algorithm to estimate IC50 values, then applied machine learning to select key lncRNAs and build a predictive model.\"},{\"question\":\"What is the main finding about RERE-AS1 and ribociclib in breast cancer cells?\",\"answer\":\"Overexpression of RERE-AS1 promotes ribociclib’s antitumor activity and suppresses malignant traits by reducing MEK and ERK phosphorylation levels.\"}]","RERE-AS1 enhances the effect of CDK4/6 inhibitor Ribociclib and suppresses malignant phenotype in breast cancer via MEK/ERK pathway | PDF",1789993872]